OSLO, Norway, Aug. 7, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.4 million in the second quarter of 2024 (Q2 2023: NOK 115.9 million) and EBITDA of NOK 27.8 million (NOK 23.4 million). Photocure reiterates…